Emmys 2012: 'Grey's Anatomy's' Sandra Oh on Cristina's Emotional Season

ABC

"Grey's Anatomy's" Sandra Oh

Sandra Oh has five Emmy nominations under her belt for her role as Grey's Anatomy's meticulous Dr. Cristina Yang, but it's the ABC medical drama's recently concluded eighth season that the actress feels has provided her best material yet.

This past season on the Shonda Rhimes-created show, Cristina faced the emotional fallout from an abortion when her marriage to Owen (Kevin McKidd) crumbled after the couple swept their baggage under the rug for too long. The story arc, which slowly progressed over the season's 24 episodes, culminated with an emotional scene in which the stoic doc threw a bowl of cereal in her husband's face before they were able to address his infidelity and begin moving on.

As if that weren't already enough, the drama also concluded its year with a plane crash that left claimed the life of one of Seattle Grace's own and left Cristina, Meredith, Derek, Mark and Arizona stranded and facing injuries both big and small. The Hollywood Reporter caught up with Oh to discuss Cristina's challenging moments of the season, saying farewell to two castmembers and the benefits of filming on location.

STORY: 'Grey's Anatomy' Recap: Who Met Their Maker in the Deadly Season Finale?

The Hollywood Reporter: This season has been particularly grueling for Cristina: an abortion, a broken marriage and infidelity, all topped off by a plane crash. Which scene did you grapple with the most? Sandra Oh: It has been an extremely challenging year that has had a lot of ups and downs, both challenging and exhilarating. A lot of the scenes that Kevin McKidd and I did of Owen and Cristina arguing in their apartment was like its own story line. We would shoot all our scenes for a day or two straight, and that was extremely challenging because emotionally and physically it becomes really exhausting. Our finale was extremely challenging physically and emotionally. So, I'd say two things -- our finale and those apartment scenes where Cristina and Owen lock themselves in and just go at it.

Cristina tosses a bowl of cereal on him, which isn't a reaction that Cristina is typically prone to. Wasn't that good? Kevin had to have cereal thrown on him eight, 10 times for that one because we did a bunch of angles. There is that one shot -- and we only did it once -- which was his close-up, which was also my best and most direct hit. He was a great sport about that. Mark Jackson directed that episode, so we had special effects make a soft bowl because I'm not actually throwing an actual ceramic bowl at him. But that was real milk and Grape Nuts. I really liked that scene because that's her first actual moment of connection with him after he tells her the truth. Even though it's physical and it's violent, it's also a connecting moment between them where she looks at him and connects again.

PHOTOS: Spoiler Alert! From 'Game of Thrones' to 'Mad Men' -- TV's Most Shocking Deaths

Cristina rarely expresses so much emotion, which she did a lot of this season. It was a slow burn that started with the season premiere and carried throughout the season, which is different that the Grey's we've seen in the past. You see her express her emotions with only two people: her best friend Meredith and her husband Owen. To see someone being pulled apart so intensely, which honestly most everyone goes through in their life in some ways, if you're lucky you're completely pulled apart and then you have to pull yourself together, which hopefully will be the exploration within hopefully the next season. It's not like we played this in a couple of episodes; we've played this throughout the entire year, and the reality of the resentments building and things not being dealt with building and betrayals happening is closer to real time in the way that we played it. Being on a show for this long, you don't have to do things boom-boom-boom because you have eight years of history and developing the character. So you can take your time with things and let it soak in, in a different and deeper way. I'm super-proud of this year. Having been on a show eight years, for me to have the richest storyline now, I'm extremely grateful.

More here:
Emmys 2012: 'Grey's Anatomy's' Sandra Oh on Cristina's Emotional Season

Kevin McKidd talks 'Brave,' 'mooning' scene, Scotland & 'Grey's Anatomy' future (Video)

Kevin McKidd of "Grey's Anatomy" fame was happy to return to his roots with Disney-Pixar's new animated film, "Brave," which is set in the Scottish kingdom of DunBroch.

In the movie, the 38-year-old actor and native of Scotland plays two characters - Lord MacGuffin and his son, Young MacGuffin. The lord and two others, Craig Ferguson's character, Lord Macintosh, and Robbie Coltrane's Lord Dingwall, present their boys to compete for the hand of Princess Merida, the film's heroine, played by Kelly MacDonald. Billy Connolly plays her father, King Fergus.

McKidd disguises his Scottish accent when he plays former US Army trauma surgeon Dr. Owen Hunt on "Grey's Anatomy," ABC's it medical drama series.

"In 'Grey's, I have to be American, I have to be quite controlled. Owen Hunt's a tortured guy and he's very serious a character," McKidd told OnTheRedCarpet.com, while talking about "Brave." "It's nice to be kind of wild and zany and Scottish for a while."

In the animated film, the male characters wear traditional kilts. In one scene, Lord Dingwall moons Lord MacGuffin and others by lifting his up in front of them, yelling: "Feast your eyes!"

"They just kind of said, 'Now he's gonna show his [butt] to you,'" McKidd said. "And I was like, 'What?' That was a lot of fun. The shame is none of us got to really hang out together, you know, Craig [Ferguson] and Billy Connolly. We're all doing separate sessions. I would have loved to have been doing all that together."

McKidd says he owns two kilts in real life and that he was taught to dance traditional Scottish dances when he was a child.

"We were taught that in PE, physical education, in Scottish school," he said. "Every boy and girl [is] taught those dances for kind of like a month and a half, at Christmas time, when it's so cold you can't go outside. You're in the gym hall and you get taught all those dances. So it's like riding a bicycle for me."

"It's so much fun, I can't tell you how much fun that dancing is for me," he added. "It's such a social thing. It breaks down so many barriers. I'm very proud of my heritage."

McKidd began his on-screen career in the 1990s. He and Macdonald both starred in the 1996 movie "Trainspotting," which deals with the drug scene in Edinburgh. The film helped launch the Hollywood career of main star and fellow Scotland native Ewan McGregor.

Read more:
Kevin McKidd talks 'Brave,' 'mooning' scene, Scotland & 'Grey's Anatomy' future (Video)

Travel Curious Often, Monthly Online Magazine, Celebrates Its First Anniversary and a Year's Worth of Visits Around …

PENSACOLA, Fla., June 25, 2012 /PRNewswire/ --Travel Curious Often has spent one full year exploring destinations around the globe. Readers saw iconic landmarks, spectacular scenery and even a few celebrities along the way! Stops included: Poland, New Orleans, Bangkok, New York, Peru, Kaua'i, Hong Kong, Paris, Rio de Janeiro and Ireland -- in fact the Irish Government Tourist Board recently named TCO one of the best travel magazines.

The TCO fan-base has increased the past year as well, because of features like Food Quest. As the name suggests, Food Quest consists primarily of restaurant critiques. But also on the menu were recipes from food bloggers and interviews with celebrity chefs -- like John Besh, Top Chef contender Marisa Churchill, and Canadian TV stars Chefs Run Wild.

Another popular segment Curious & Thirsty has taken readers on excursions to coffee plantations in Kaua'i, vodka distilleries in Poland, and wineries throughout Napa and Sonoma, with a tour of the legendary Far Niente for a chat with proprietress Beth Nickel.

Publisher Marla Norman-Freytag continues to scout out unique properties to present in Hotel Finds. Past reviews included Sanctuary Lodge, the only hotel at Machu Picchu and the historic Gramercy Park Hotel in New York City -- with a lively report about stars who book into the property: Lady Gaga, Daniel Craig, Rihanna and Eva Longoria. The tallest hotel in the world, The Ritz Carlton Hong Kong, has also been featured along with a 200-acre ranch in the Texas Hill Country where guests can mingle with herds of wild Axis Deer and Elk. Lots of variety in just one year.

Each issue of Travel Curious Often provides videos, maps, links to hotels, restaurants, and bars -- all the usual gadgets to help readers stay on the right path. But the Pronunciation tab continues to fascinate readers above all. Recordings by native speakers -- of French, German, Spanish, Thai, Polish, Chinese and Hawaiian -- reciting the names of local places helps travelers to acclimate anywhere.

Finally the newly added TCO Store is a destination in and of itself, with great travel gear, cute road-worthy clothing for men & women, and souvenirs from all the places featured in Travel Curious Often. The TCO Store is truly one-stop shopping for busy globetrotters.

Travel Curious Often covered plenty of ground its first year. But the TCO staff is confident that this is just the beginning of a very long adventure. Hop onboard!

Contact Marla Norman-Freytag, publisher, for additional information or permission to reprint TRAVEL CURIOUS OFTEN articles and photos: marlanorman@travelcuriousoften.com or 786-200-6241

This press release was issued through eReleases Press Release Distribution. For more information, visit http://www.ereleases.com.

Visit link:

Travel Curious Often, Monthly Online Magazine, Celebrates Its First Anniversary and a Year's Worth of Visits Around ...

HipGeo and Rough Guides Team to Provide New Way to Share Travel Adventures Instantly Using iPhone and iPad Photos and …

FULLERTON, Calif.--(BUSINESS WIRE)--

HipGeo and Rough Guides are proud to announce the Rough Guide Trip Lens app for iPad and iPhone is now available and free to download from the App Store. Now, for the first time, users can transform a collection of individual iPhone photos and text into a creative narrative of travel adventures under the respected Rough Guide brand.

Rough Guide Trip Lens presents the newest way to document and share travel adventures. The jointly developed Rough Guide Trip Lens app uses unique location-based technology to pinpoint the users location, helping travellers connect with family and friends back home and record their journey as it happens; transforming photos and text into a creative narrative of their travel adventures.

Travellers can post photos and text from anywhere in the world, and watch their travels unfold on a map at each destination, creating a continuous and cohesive story of their journey. Locations and photos can also be shared instantly in the app via Facebook and Twitter, and link to a website that compiles all the photos from the journey into a personalized blog for friends and family to see.

Travellers can find inspiration from the adventures of other users, instantly becoming part of a community of other travellers who are sharing their experiences, and, if no WiFi is available, all posts are saved and automatically uploaded once connected.

Rich Rygg, co-founder of HipGeo said: Combining the travel know-how of Rough Guides with a custom version of our app means that whether people are memorializing adventures locally or from far away, theyre telling continuous and cohesive stories about their adventures in a way never before possible. Everyone wants to capture and share memories about the coolest places on the planet and this is the ultimate way to share those journeys virtually.

Peter Buckley, Digital Publisher for Rough Guides said: We know that travellers want to capture and share their experiences in the easiest way possible while theyre on the go. This is therefore the ultimate travellers app, allowing them to do that whilst instantly connecting them to a community of like-minded travellers who are also seeking exciting adventures.

About Rough Guides

Rough Guides is a leading travel content provider with more than 700 travel guides, gift-books, reference titles, maps, phrasebooks, bespoke custom publishing guides and digital products, including eBooks and mobile applications. Start your journey at http://www.roughguides.com and whatever you do, Make The Most Of Your Time On Earth

About HipGeo

More:

HipGeo and Rough Guides Team to Provide New Way to Share Travel Adventures Instantly Using iPhone and iPad Photos and ...

Shutter Tours Earns 2012 Tripadvisor Certificate of Excellence

Honored as a Highly Rated Sightseeing and Photography Tour Company as Reviewed by Travelers on the World’s Largest Travel SiteSeattle, Washington (PRWEB) June 25, 2012 Shutter Tours, a sightseeing and photography tour company, today announced that it has received a TripAdvisor® Certificate of Excellence award. The accolade, which honors hospitality excellence, is given only to establishments ...

Originally posted here:

Shutter Tours Earns 2012 Tripadvisor Certificate of Excellence

Watch #7.Transformers Games Review Part 2: Transformers The Movie 2007 By William Cosh – – Video

23-06-2012 12:29 Watch Full Movie Here Transformers for Game Transformers Games Transformers Games For Kids Transformers Games for kids Transformer Games Transformers (toy Line) of Review William the transformers revenge Gameplay Cosh tips & tricks ati radeon series play games online Cybertron ignentertainment Dark extreme driving playstation super computer Transformers 2 revenge fallen asome game hd Multiplayer Video Game Moon Pc game play Commentary commentary Devastator gameplay video review Revenge Fall 047875842281 047875841383 clevvergames playstation3 thestudgames Bumblebee 8RODIMUS Optimus flash games Fallen The Decepticons 47875841383 automobiles environment games video game bubble bee Deathmatch technology angrybirds xbox360 Part megan fox airplanes cybertron unlimited adventure official animated revenge Online Convoy Prime movie game Autobots consoles analysis tutorial destroid cyberton Defender upcoming download portable terrible bruticus highmoon grimlock nintendo trailer optimus fallen video Game: 4850 hd station Network Detroit weapons toysrus Dungeon Pinball classic hockey2 Perfect Android release

Read this article:

Watch #7.Transformers Games Review Part 2: Transformers The Movie 2007 By William Cosh - - Video

Bioheart's Chief Science Officer Kristin Comella Presents at 10th Annual Meeting of International Society for Stem …

SUNRISE, Fla., June 25, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that Kristin Comella, the company's Chief Science Officer presented at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan June 13 - 16, 2012. One of the world's premier stem cell research events, the ISSCR format includes international research and poster presentations from invited speakers, exceptional peer-to-peer learning and unparalleled networking opportunities.

Comella presented a poster on clinical applications of adipose or fat derived stem cells (ADSCs).

The ISSCR annual meeting serves as the largest forum for stem cell and regenerative medicine professionals from around the world. Through lectures, symposia, workshops, and events attendees experience innovative stem cell and regenerative medicine research, advances and what's on the horizon. The meeting features more than 1,000 abstracts, nearly 150 speakers and provides numerous networking and professional development opportunities and social events. For additional information, visit http://www.isscr.org.

Kristin Comella has over 14 years experience in corporate entities with expertise in regenerative medicine, training and education, research, product development and senior management including more than 10 years of cell culturing experience. She has made a significant contribution to Bioheart's product development, manufacturing and quality systems since she joined the company in September 2004.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended March 30, 2012.

View post:

Bioheart's Chief Science Officer Kristin Comella Presents at 10th Annual Meeting of International Society for Stem ...

NeoStem Awarded NIAID Research Grant for the Development of VSEL Technology for Radiation Exposure

NEW YORK, June 25, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a cell therapy company, today announced that it has been awarded a two year grant totaling $595,252 for the "Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) Stem Cells as a Countermeasure to Radiation Threat" from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). This peer reviewed grant was awarded to support research to be headed by Denis O. Rodgerson, Ph.D., Director of Stem Cell Science for NeoStem and Mariusz Ratajczak, M.D., Ph.D., who is the head of the Stem Cell Biology Program at the James Graham Brown Cancer Center at the University of Louisville and co-inventor of VSELTM Technology.

This award will fund studies to investigate the potential of very small embryonic-like stem cells as a countermeasure to radiological and nuclear threat. The product candidate, which is an autologous stem cell therapy derived from the patient's own stem cells, will be developed to rescue patients who have been exposed to radiation due to nuclear accident or terrorist threat and to treat cancer patients who have undergone radiation therapy and who consequently have compromised immune systems. The award includes $295,252 for the first year and $300,000 for the second year of the project.

Dr. Denis O. Rodgerson, Director of Stem Cell Science for NeoStem, said, "We are very excited to add radiation treatment to the growing list of indications for which our VSELTM Technology is being evaluated. Those exposed to acute high-dose radiation have compromised immune systems such that the virulence and infectivity of biological agents is dramatically increased. Death can occur within 1-6 weeks following radiation exposure. Currently there is only one intervention that saves a fatally irradiated person -- a rescue through stem cell transplantation. VSELs might be an ideal cell therapy to regenerate the body's immune system and repair other tissues damaged by radiation exposure. Most importantly, early studies show VSELs are resistant to lethal radiation which destroys other immune system restoring stem cells in the body, making autologous treatment post-exposure possible."

Dr. Robin L. Smith, Chairman and CEO of NeoStem, added, "NeoStem is pleased that the NIAID is funding this cutting edge technology that we hope will reinvent the treatment landscape for acute radiation syndrome. We plan to continue to pursue NIH SBIR grants to fund our VSEL technology platform development with non-dilutive capital."

About VSELTM Technology

NeoStem has a worldwide exclusive license to VSELTM Technology. Research by Dr. Mariusz Ratajczak, M.D., Ph.D., and others at the University of Louisville provides compelling evidence that bone marrow contains a heterogeneous population of stem cells that have properties similar to those of an embryonic stem cell. These cells are referred to as very small embryonic-like stem cells. This finding opens the possibility of capturing some of the key advantages associated with embryonic stem cells without the ethical or moral dilemmas and without some of the potential negative biological effects associated with stem cells of embryonic derivation. The possibility of autologous VSEL treatments is yet another important potential benefit to this unique population of adult stem cells. VSELTM Technology offers the potential to go beyond the paracrine effect, yielding cells that actually differentiate into the target tissue creating true cellular regeneration.

About NeoStem, Inc.

NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and Amorcyte is enrolling patients for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial by 2012/2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements

Read more:

NeoStem Awarded NIAID Research Grant for the Development of VSEL Technology for Radiation Exposure

Religious leader visits Columbia

Myriad colors and cultures mixed Sunday in Columbia when more than 100 devotees of the ultimate humanitarian gathered to celebrate a gift of spiritual enlightenment and their leaders birthday.

The city was the site of a divya milan, a divine meeting, with the man known as His Divine Holiness Acharya Swaminshree Purushottampriyadasji Maharaj, or Bapa to celebrants, the leader of Shree Swaminarayan Gadi Sansthan a Hindu sect based on the preservation of moral and cultural values.

Shashi Kerai, one of the organizers of Sundays gathering at Columbias American Legion Post 19 and president of the Shree Muktajeevan Academy of Excellence in Chicago, said the visit is incredibly rare. Every year, he said, Maharaj and several saints tour the world to spread the faiths message of peace, tolerance and understanding of all religions and nations. Nearly 30 other U.S. cities had been nominated by followers to host the spiritual leader but did not make the final list of seven stops.

He visits Europe, London, the Far East, America and so forth. This countrys a really big country, so he cannot accommodate every city, Kerai said. Columbia is the most fortunate this year along with Los Angeles, Chicago to be nominated to receive him and to celebrate his arrival.

For their leaders 70th birthday, which he celebrated last month, congregants melded their cultures oldest traditions with all the trimmings of an American party.

As a traditional parade of followers circled the legion hall to bless and bring peace to the land, the crack of party poppers broke out of the cacophony of singing voices, clapping hands and clinking bangles.

Kerai, who works as a surgical neurophysiologist when he is not traveling on behalf of his faith, said much of the celebration is also to instill a sense of heritage and culture in congregants young and old. For followers, the event is as big if not bigger than a visit from the Pope of the Catholic faith, he said.

In recognition of the meetings host, American Legion Post 19 Post Commander Bob Stephenson and First Vice Commander Gary Fisher were blessed by His Divine Holiness. Fisher said the post was blessed to be chosen for the visit.

Kerai said that because of the number of devotees living and working in Tennessee, its possible that a temple could be constructed sometime in the near future, but it remains uncertain where. Until then, he said local congregants will continue to promote the morality and performance of charitable acts of their faith.

To obtain more information on His Divine Holiness and his teachings, visit http://www.swaminarayangadi.com.

See the article here:

Religious leader visits Columbia

Youkilis Heads to White Sox

The Red Sox have traded veteran third baseman Kevin Youkilis to the White Sox, Chicago's South Siders have confirmed.

The three-time American League All-Star third baseman was acquired in exchange for infielder Brent Lillibridge and right-handed pitcher Zach Stewart. The White Sox also received a cash payment in the trade.

According to TV station WBZ, Youkilis tipped his helmet, blew a kiss to the crowd before leaving Sunday's game.

Youkilis was a member of Red Sox World Championship teams in 2004 and 2007, the White Sox pointed out in a statement. He ranks among the clubs all-time postseason leaders and is hitting .225 with four home runs and 13 RBI in 41 games this season.

He was on the disabled list in May with lower back tightness.

Original post:

Youkilis Heads to White Sox

Open For Business: NASA Launches New Technology Transfer Portal

Mon, Jun 25, 2012

In an effort to accelerate technology transfer from NASA into the hands of American businesses, industry and the public, the agency's new Technology Transfer Portal is open for business.

NASA's Technology Transfer Portal provides an Internet-based one-stop front door to the agency's unique intellectual property assets available for technology transfer and infusion into America's new technology and innovation-driven economy. NASA's Technology Transfer Program allows research and development to transfer back into the U.S. economy via licenses, patents and intellectual property agreements that often result in new innovations, products and businesses. The use of NASA technology by American businesses spurs job growth and helps maintain U.S. economic competitiveness while improving our everyday lives.

"One of NASA's highest priority goals is to streamline its technology transfer procedures, support additional government-industry collaboration and encourage the commercialization of novel technologies flowing from our federal laboratories," said NASA Administrator Charles Bolden at NASA Headquarters in Washington. "One way NASA can streamline and increase the rate of aerospace technology transfer is through tools like NASA's Technology Transfer Portal."

NASA designs technologies to solve difficult problems in space and on Earth. Some examples include NASA-developed devices designed to operate remotely and with limited servicing in the harsh environment of space, and strong and lightweight materials that can withstand the extreme temperatures of supersonic flight or space travel. NASA has designed lifesaving techniques, protocols, and tools for use when orbiting the Earth and the nearest doctor is more than 200 miles below. Closed environment recycling systems, as well as energy generation and storage methods also have useful applications here on Earth.

NASA's new tech portal simplifies and speeds access to the agency's intellectual property portfolio, much of which is available for licensing. The site features a searchable, categorized database of NASA's patents, a module for reaching out to a NASA technology transfer specialist and articles about past successful commercialization of NASA technology. Historical and real-time data for NASA's technology transfer program also are available.

"A priority of NASA is to get federally-funded new technologies into the commercial marketplace," said NASA Chief Technologist Mason Peck. "We're hopeful that entrepreneurs, businesses of all sizes and anyone looking for innovative solutions to technology problems will explore NASA's Technology Transfer Portal to find opportunities to transfer NASA technologies into innovative solutions for the nation."

More here:

Open For Business: NASA Launches New Technology Transfer Portal

What NASA’s Next Mars Rover Will Discover

NASAs Mars Science Laboratory is on its way. In a little more than a month, the 1-ton rover, which launched in November, will descend to the Martian surface.

The nuclear-powered robot is designed to make spectacular new discoveries about the Red Planet. It will drill and analyze the Martian soil to search for signs of water, past or present, and determine whether or not the planet was ever able to support life.

MSL dwarfs its immediate predecessors, the rovers Spirit and Opportunity and could almost crush the first Martian rover, Sojourner, beneath one wheel. Bringing a robot this large down safely necessitates a never-before-attempted landing system, though the increased size has let scientists pack 10 state-of-the-art instruments aboard and should allow the robot to rove farther than any before.

Every time we land a new rover on Mars, our ability to understand the surface increases tremendously, said geologist John Grotzinger of Caltech who is the project scientist for the mission.

While scientists dont know exactly what new findings await the rover, they have good ideas of what they want to look for. The first few weeks of MSLs life on Mars are already planned out in detail and after the mission starts in earnest, researchers have a number of targets they are eager to explore.

Here, Wired takes a look at MSLs game plan after it gets its wheels on the ground on Aug. 5, and the early discoveries scientists are hoping to make.

Above:

MSLs sky crane represents a brand new way to get a rover down to the surface of Mars. When the lander approaches the ground, it will fire rockets and hover 25 feet over the surface and then gently lower the robot down on wires. This landing system represents the limits of current technology, making MSL the largest mass to ever touch down on the Red Planet.

The new method doesnt ruffle the science team too much.

Were actually really excited about the fact that weve got this guided entry capability, said Grotzinger, adding that it allowed researchers to pinpoint their landing site with greater precision than ever. People get nervous about sky crane, but its really a better landing system from a safety point of view.

Here is the original post:

What NASA’s Next Mars Rover Will Discover

R&D: Molecular medicine excellence

TheInstitute for Research in Molecular Medicine (INFORMM) began as a multi-disciplinary cluster-based research programme spearheaded by 11 principal researchers from the Schools of Medical Sciences, Dental Sciences, Health Sciences and MITD (Medical Innovation and Technology Development Unit) located at the USM Health Campus in Kelantan. In 2003, after a rigorous audit exercise INFORMM was established following a formalised recognition accorded by the university and the Ministry of Higher Education. This was also the first time in the history of USM that an institute was formed bottom-upthrough efforts of a group of researchers in a cluster.

From the initial members of the loose research cluster, INFORMM now boasts 20 full-time PhD qualified lecturers. The multidisciplinary character of the institution has been maintained and is reflected in the staff development plan of its younger members, who have been trained in the latest techniques in biotechnology and molecular biology. This has enabled the institution to grow from strength to strength, culminating in it being recognised as a Higher Education Centre of Excellence (HiCoE) by the Ministry of Higher Education in 2008.

Physically, INFORMM straddles East and West Malaysia, having a purpose-built building in both the Kelantan and Penang campuses of USM. Within these two facilities are housed roughly 90 postgraduate students doing full-time research in molecular medicine. Research at INFORMM is cluster-based, concentrated on translational and fundamental research. Each research cluster comprises a group of scientists with differing expertise but with a common research focus area.

Contributions from these individual scientists towards a common goal help to focus and accelerate research findings and optimise research output. In practice, research in INFORMM adopts the R-D-C-E (Research - Development - Commercialisation - Entrepreneurship) concept, where research development and innovation are performed under one roof to bring the innovation to the marketplace in a timely manner. These approaches have led INFORMM to achieve success in its research output and subsequently transform these into commercialised products or licensed technology. The R-D-C-E approach adopted by INFORMM for its research and innovation activities is also now subscribed by many research organisations in Malaysia.

Grooming Postgraduate Students: In a short space of less than 10 years, INFORMM has successfully obtained research grants of more than RM26 million and the research output, measured by the number of publications and cumulative impact factors, have been steadily increasing. The institute has also seen success in the commercialisation and licensing of its innovations. As with any other research institution, while the fundamental knowledge, ideas and inspiration comes from the academia, the output and successes will not be possible without industrious postgraduate students.

INFORMM encourages and recruits bright and promising students from all over the world to join the institute as postgraduate students in order to catapult INFORMM to a world-class level. Currently the postgraduate enrolment is 90 students with 60 per cent pursuing their masters studies, and 40 per cent, their doctorates. The number of students is expected to exceed 100 this year.

As the student numbers approach saturation, the emphasis will be on increasing the percentage of high quality doctorate students. This is seen as a natural progression as the institute matures, and the quality of its research will be its ultimate sustaining factor.

Whilst it is assumed that postgraduate students need to spend hours upon hours acquiring specialised skills and running experiments, those at INFORMM also receive an all-round education, in addition to the technical skills that are needed for their research. During their stint in the institute, they undergo soft skill development, communication skills development and project management skills.

Weekly journal club presentations, annual students colloquiums, regular technology enhancement lectures and invited speaker lectures are practised. This year, an element of entrepreneurial training and exposure is being introduced as a soft start to academic entrepreneurship. This is seen as very relevant, to the R-D-C-E concept, which has shown good results in a relatively short time. The postgraduate students also work in an ISO 9001 regulated environment and are trained to adhere to the standard operating procedures and management practices of INFORMM. INFORMM is constantly in dialogue using regular student-director meetings to ensure they receive the best training possible as scientists as well as future engineers in the nations development.

See original here:

R&D: Molecular medicine excellence

Badass Naruto …. RE-UPLOAD! – Video

24-06-2012 12:49 Two strikes! Hurry! Sub zeh back-up! Re-uploading this upon request :3 Not too much to say about this amv ... I remember when I first started working on it how I told my friend that I was super psyched about it and thought it to be one of my greatest creations x'D Soon after I detested it and realized all the errors within it ee' What can I say ... ? The harshest critic is always yourself lol vv' But don't mind me~

See more here:

Badass Naruto .... RE-UPLOAD! - Video

Huit Denim Co: The jeans with the app that tells their history

Howies founders David and Clare Hieatt have launched a new venture, Hiut Denim Co, to revive Cardigan's denim industry

BY Georgia Dehn | 23 March 2012

In May last year the entrepreneur David Hieatt appeared on the front page of his local newspaper in Cardigan, west Wales, appealing for skilled machinists with specialist knowledge of making jeans to work in a new denim factory in the area. Hieatt, who founded the action sports clothing company Howies in 1995 with his wife, Clare (they sold it to Timberland in 2006), was in the process of launching a new venture, Hiut Denim Co. In response to the newspaper article, he was inundated with applications from locals, many of whom said the same thing: 'I want to make jeans again.'

Almost a decade ago, 400 people in Cardigan, a tenth of the town's population, with hundreds of years' experience making jeans between them, were made redundant when the Dewhirst Group shut the doors to its clothing factory and moved production to Morocco. Dewhirst was Cardigan's biggest employer and the factory had been producing 35,000 pairs of jeans each week for the likes of Marks & Spencer and Gap. Hieatt wanted to give locals the opportunity to put their skills to good use again. He rented an industrial unit, in which the company has now been installed for three months. The walls are clad in pitch pine from an old flour mill and Hieatt bought 24 sewing machines from an old Wrangler factory in Poland. After interviewing 'lots of eager women' who used to work at Dewhirst, he hired three and named them his 'Grand Masters'. Hieatt also took on a cutter who had worked at Dewhirst for 38 years, and a mechanic to fix the machines when they went wrong.

Hiut Denim Co may be a tiny start-up, but 'Levi's started small too,' Hieatt says. 'Our aim for the first year is to sell 2,500 pairs of jeans.' Mostly they will be sold online, but also in about 20 specialist denim shops around the world. Hieatt wants to build up the company so that he can offer everyone who worked at Dewhirst their old job back: 'We have to get everyone in this town making jeans again.' At a time when provenance matters greatly to consumers, manufacturing his product in Britain gives Hiut Denim Co a head start in the market, but Hieatt says he 'can't count on craftsmanship alone'. What he needs to do, he says, is to 'change the jeans industry through ideas.'

Hieatt is an ideas man and always has been. Before establishing Howies, he worked as a copywriter at the Saatchi & Saatchi advertising agency in London. 'I was working with bright and driven people,' he says. After Howies, he and Clare founded the Do Lectures - a five-day event (now in its fifth year) at an upmarket campsite in west Wales to which they invite inspiring individuals from around the world, including authors and entrepreneurs, to 'come and tell us what they do'. It is essentially a festival of good ideas, a 'Glastonbury of the mind'.

Hieatt has called on some of his more technologically minded friends to help him with his big idea for Hiut Denim Co. 'We are building an app called History Tag,' he says, 'and our jeans will be the first in the world that will have their whole history recorded.' To start with, Hiut Denim Co will sell two styles (men's only): one in selvage denim (sourced in Japan), the unwashed, raw, real indigo kind; and one in organic denim (sourced in Turkey). Each pair produced will have a code sewn into them and at each stage of production Hieatt's Grand Masters will photograph the jeans for the History Tag app - 'so when you buy a pair of jeans you will not only get a receipt, you will get pictures of your jeans being born. As you go through your life with your jeans you will be able to upload all your pictures of where you go and what you did wearing them,' he says. 'Then when those jeans are handed down or end up in a second-hand store, their history will go along with them too. This idea will become a badge of honour for companies who make products that last, and the longer you make something last the more stories it has to tell.'

hiutdenim.co.uk

Read the original post:

Huit Denim Co: The jeans with the app that tells their history

TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine

TAIPEI, June 25, 2012 /PRNewswire-Asia/ -- TaiGen Biotechnology Company, Limited ("TaiGen") and Zhejiang Medicine Company, Limited ("ZMC") today announced that they have signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau). Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. TaiGen will be responsible for completing the Phase 3 clinical trial for community acquired pneumonia ("CAP") in China. ZMC will be responsible for manufacturing, sales and marketing of nemonoxacin in China through its wholly-owned subsidiary, XinChang Pharmaceuticals. TaiGen will retain full development and commercialization rights outside the licensed territory including Taiwan, the United States, European Union, and Japan. Under the terms of the agreement, TaiGen will receive an upfront payment of US$ 8 million from ZMC and will receive additional milestones as well as royalties on product sales. The term of the agreement is 20 years.

Nemonoxacin has demonstrated efficacy and safety in CAP and diabetic foot infection in multinational and multi-center clinical trials conducted by TaiGen. In particular, nemonoxacin has excellent activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA. Nemonoxacin is taken once-a-day and available in both oral and intravenous formulations. Currently, TaiGen is completing a Phase 3 CAP trial with more than 500 patients from Taiwan and mainland China and expects to file new drug applications in Taiwan and mainland China simultaneously in early 2013.

China is one of the major antibiotic markets in the world. According to IMS, the sales of antibiotics in 2011 were approximately US$ 11 billion (RMB 68 billion) and account for almost 20% of the total pharmaceuticals sales. Rate of antibiotic resistant infections in China is among the highest in the world.

Mr. Li Chun Bo, Chairman of the ZMC, commented, "We are impressed with nemonoxacin's broad spectrum activity towards drug-resistant bacteria, in particular, MRSA, and excellent safety profile. We are excited to establish this partnership with TaiGen because of its reputation as a premier research-based biotech company in Asia. This partnership will break new ground for cross-strait collaboration in the pharmaceutical industry. Nemonoxacin will be a major addition to ZMC's antibiotic product line and significant profit driver".

Dr. Ming-Chu Hsu, President and Chief Executive Officer of TaiGen, said, "China is the world's fastest growing pharmaceutical market. It is poised to overtake Japan as the second largest pharmaceutical market. We are extremely please to establish our nemonoxacin partnership with ZMC, a first-class pharmaceutical company and major player in the Chinese antibiotics market. With nemonoxacin, TaiGen and ZMC together will bring new medicine to treat unmet medical needs in China. This partnership will not only set a new record for pharmaceutical licensing involving a Taiwanese and a mainland Chinese company but hopefully will also become a model of the future collaborations," Dr. Hsu also added, "With the conclusion of the partnership in China, we will actively pursue nemonoxacin licensing discussions in other territories such as European Union."

About Zhejiang Medicine

Zhejiang Medicine Company, Limited is a leading pharmaceutical company in China specializing in sales and distribution of pharmaceuticals and manufacturing of active pharmaceutical ingredients (vitamins and antibiotics). Its sales revenue in 2011 is US $740 million (RMB 4.8 billion). ZMC is a leader in the Chinese antibiotic market with levofloxacin, vancomycin, and teicoplanin in the product line. ZMC's Lai Li Xin, a branded levofloxacin, is one of the top selling antibiotics in China with 2011 sales exceeding US $110 million (RMB 735 million). In addition to pharmaceuticals sales, ZMC is also known for its manufacturing quality. Its vancomycin active pharmaceutical ingredient has obtained GMP qualification from US Food and Drug Administration (FDA) and exported to western countries. ZMC is publicly listed in the Shanghai Stock Exchange (600216) and has a market capitalization of RMB 11 billion.

About TaiGen Biotechnology

TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, mainland China. TaiGen has full discovery research capacity in Taiwan and clinical development in mainland China/Taiwan/US. In addition to nemonoxacin, TaiGen has two other in-house discovered new chemical entities in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, in Phase 2 and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infection, in Phase 1. Both TG-0054 and TG-2349 are currently in clinical development in the US.

Disclaimer

Link:

TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine

WNBA: McCoughtry returns as Dream trip Liberty

NEWARK, N.J. (AP) -- The Atlanta Dream didn't panic when the New York Liberty made a run late in the first half to take a lead at the break. They just regrouped and took control of the game in the third quarter.

Angel McCoughtry scored 23 points and Sancho Lyttle added 19 to lead the Dream to a 74-64 victory Sunday.

"We just can't let outside things get in our head," McCoughtry said when asked what the team discussed after giving up a 10-point lead and trailing by two at halftime. "We were a little frustrated with some calls, a little frustrated with the way we were playing, and how they were making their run. It's called adversity, it happens. It's the game."

McCoughtry was 7-for-20 from the field and 8-for-10 on free throws in her return after missing two games due to a knee injury, helping the Dream (5-7) snap a two-game skid.

Lyttle scored nine points, Armintie Price had five and McCoughtry added five points and four rebounds as Atlanta outscored New York 25-10 in the third quarter to take a 13-point lead.

"It's not because of me. It's a team effort and everybody coming together, regrouping after a loss," McCoughtry said. "(Lyttle) hit a couple of 3s ... she has the highest 3-point percentage shooting on the team and she's a post player. Armintie got some great rebounds, got fouled. Lindsey (Harding) is coming back slowly."

Leilani Mitchell scored 16 points, Kara Braxton had 14 points and 13 rebounds, and Cappie Pondexter and DeMya Walker added 12 points each as the Liberty (4-9) lost for the fourth time in five games. New York's lone win during that stretch came at Atlanta last Tuesday in a game McCoughtry missed.

Pondexter fouled out of the game late in the fourth quarter as the Liberty were trying to make a surge. She finished 4 for 17 from the field with seven turnovers.

"We couldn't make shots tonight," Pondexter said. "They did a great job of adjusting. We were the last game they played and obviously they made a lot of adjustments. ... We just got to learn to be consistent. It's kind of up and down, it's kind of hard for us to get it together."

The Liberty had 26 turnovers, which led to 31 points for the Dream. Atlanta had 16 turnovers, leading to nine points for New York.

See the article here:

WNBA: McCoughtry returns as Dream trip Liberty